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In recent years, various research groups have described
opioid receptor (OR)-active molecules lacking some
crucial pharmacological requisites. In particular,
several papers have stressed the role of Tyr1 in the
interaction of native or synthetic opioid peptides with
l-opioid receptors (MORs). In certain cases, the
Keywords
atypical agonist; cyclopentapeptide; induced
fit; molecular docking; opioid receptor
Correspondence
L. Gentilucci, Dipartimento di Chimica ‘G.
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Endogenous and exogenous opiates are currently considered the drugs of
choice for treating different kinds of pain. However, their prolonged use
produces several adverse symptoms, and in addition, many forms of pain
are resistant to any kind of therapy. Therefore, the discovery of com-
pounds active towards l-opioid receptors (MORs) by alternative pharma-
cological mechanisms could be of value for developing novel classes of
analgesics. There is evidence that some unusual molecules can bind opioid
receptors, albeit lacking some of the typical opioid pharmacophoric fea-
tures. In particular, the recent discovery of a few compounds that showed
agonist behavior even in the absence of the primary pharmacophore,
namely a protonable amine, led to a rediscussion of the importance of ionic
interactions in stabilizing the ligand–receptor complex and in activating sig-
nal transduction. Very recently, we synthesized a library of cyclic analogs
of the endogenous, MOR-selective agonist endomorphin-1 (YPWF-NH2),
containing a Gly5 bridge between Tyr1 and Phe4. The cyclopeptide
c[YpwFG] showed good affinity and agonist behavior. This atypical MOR
agonist does not have the protonable Tyr amine. In order to gain more
information about plausible mechanisms of interaction between c[YpwFG]
and the opioid receptor, we synthesized a selected set of derivatives con-
taining different bridges between Tyr1 and Phe4, and tested their affinities
towards l-opioid receptors. We performed conformational analysis of the
cyclopeptides by NMR spectroscopy and molecular dynamics, and investi-
gated plausible, unprecedented modes of interaction with the MOR by
molecular docking. The successive quantum mechanics ⁄molecular mechan-
ics investigation of the complexes obtained by the molecular docking pro-
cedure furnished a more detailed description of the binding mode and the
electronic properties of the ligands. The comparison with the binding mode
of the potent agonist JOM-6 seems to indicate that the cyclic endomor-
phin-1 analogs interact with the receptor by way of an alternative mecha-
nism, still maintaining the ability to activate the receptor.
Abbreviations
Aib, a-aminoisobutyric acid; CPP, cyclopentapeptide; DAMGO, H-Tyr-D-Ala-Gly-N-MePhe-glyol; DOR, d-opioid receptor; DPPA,
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modification of the phenolic OH group had no conse-
quences for the ability to bind the receptor. Indeed,
the transposition [1,2], removal [3,4], duplication [5] or
substitution with a surrogate [6] of Tyr1 gave analogs
that showed comparable binding affinities and poten-
cies to those of the parent peptides.
A more relevant modification is the removal or
derivatization of the positively charged N-terminal
amino group. In general, these modifications are
responsible for transforming agonists into antago-
nists, confirming the fundamental role of the amino
group in receptor activation. Noteworthy examples
are the somewhat d-opioid receptor (DOR)-selective
casomorphin derivatives, in which the terminal amino
group is eliminated or formylated [7], the carbamate-
peptide PhCH2OC(O)–Pro–Trp–PheNH2, which
showed nanomolar affinity for MORs [8], the potent
enkephalin-derived DOR antagonist containing a
deaminated Tyr [9], the enkephalin and j-opioid
receptor (KOR)-selective DynA analogs obtained by
replacement of Tyr1 with 3-(2¢,6¢-dimethyl-4¢-hydro-
xyphenyl)propanoic acid and (2S)-2-methyl-3-(2¢,6¢-
dimethyl-4¢-hydroxyphenyl)-propionic acid (Mdp) [10],
and finally the cyclic DynA analog lacking the basic
N-terminus, which showed good KOR affinity [11].
In contrast, a few compounds lacking the amino
group have demonstrated an agonist nature: the MOR-
selective bicyclic compound 1, designed to mimic
enkephalin or endomorphin b-turn models, the j-selec-
tive neoclerodane diterpene salvinorin A (com-
pound 2), and the cyclic endomorphin-1 (EM-1)
analog active towards MOR c[YpwFG] (compound 3)
(Fig. 1).
The highly constrained 6,6-bicyclic compound 1,
which has no N-terminal amino group, showed an ini-
tial level of analgesic activity similar to that of mor-
phine, but with a shorter in vivo half-life [12]. On the
basis of 2D-NMR analysis and molecular mechanics
(MM) computations, the authors noticed a certain
superimposition of the structure of compound 1 with a
trans-EM-1 type III b-turn-like structure. According to
this partial superimposition and the MOR selectivity
profile, they implicitly suggested that the interaction of
compound 1 with the receptor could mimic that of
EM-1 or enkephalins, even in the absence of a ionic
interaction.
Salvinorin A (compound 2), a naturally occurring
hallucinogen isolated from Salvia divinorum [13], is a
unique, non-nitrogen-containing selective KOR ago-
nist. An earlier docking analysis, based in turn on
models originally developed for non-opioid KOR
agonists such as U69593 [14], led to a preliminary
model. However, by using an improved model of the
receptor, and screening of salvinorin derivatives [15],
the same authors substantially modified the original
model [16]. More recently, acquired structure–function
data of salvinorin analogs [17,18] led to the proposal
of a third different model [19].
The cyclopeptide compound 3, c[YpwFG], showed
good MOR affinity (Table 1), and agonist behavior
(forskolin-stimulated cAMP production inhibition test)
[20]. Cyclic peptides have been widely used as con-
formationally restricted frameworks [21], useful for
arranging the pharmacophores in different reciprocal
orientations, and in particular, cyclic pentapeptides
containing one or two d-amino acids have been suc-
cessfully utilized as b-turn or c-turn models [22–27].
The hypothesis that EM-1 derivatives could adopt at
the receptor a folded structure stabilized by some kind
of c-turn or b-turn has been stressed in recent papers
[8,28,29].
For the atypical structure and the highly lipophilic
character, we planned further studies to provide
insights into how c[YpwFG] might interact with the
receptor. We synthesized and tested a selected
mini-library of new cyclopeptides derived from com-
pound 3, and we performed a computational investiga-
tion intended to investigate the possible orientations of
the biologically active cyclopeptides when docked into
the binding site defined by the MOR model. We first
Fig. 1. Examples of opioid agonists lacking a protonable amino group.
The atypical opioid agonist c[YpwFG] L. Gentilucci et al.
2316 FEBS Journal 275 (2008) 2315–2337 ª 2008 The Authors Journal compilation ª 2008 FEBS
explored the possible binding positions and binding
modes of the ligand within the rigid receptor environ-
ment, and the solutions obtained from this docking
study were subsequently optimized by means of the
combined quantum mechanics QM ⁄MM approach,
using a flexible receptor environment that allows for
simulation of the receptor adaptation upon ligand
binding (induced fit). The conformations adopted in
dimethylsulfoxide were used as starting structures for
docking the ligands into the entire channel pore with
autodock [30], without prior specification of the bind-
ing site, by using the so-called ‘blind docking’
approach, a technique introduced for the detection of
possible binding sites and modes of binding of peptide
ligands by searching the entire surface of protein tar-
gets [31,32]. The main potential orientations have been
evaluated using the QM ⁄MM optimization of the com-
plexes [33,34], providing a more detailed description of
the binding mode and the electronic and steric proper-
ties of the c[YpwFG] ligand.
Results
Synthesis and pharmacological characterization
of the cyclopeptides c[YpwFXaa]
We synthesized compound 3 as a member of a series
of conformationally restricted EM-1 (YPWF-NH2)
derivatives having the first and fourth residues con-
nected by a simple Gly bridge [20]. To define the best
spatial disposition of the aromatic side chains for an
optimal ligand–receptor interaction, we introduced
each 1–4 residue in the d-configuration or l-configura-
tion, generating a library of stereoisomeric, 3D
distinct cyclopentaptides. Among the diverse stereo-
isomers of the library, only compound 3 of sequence
c[YpwFG] showed a satisfactory affinity for MORs
[20].
Cyclopentapeptides (CPPs) are expected to be rela-
tively conformationally homogeneous. It has been well
documented that for most CPPs, the overall conforma-
tion depends on the specific sequence of residue chiral-
ity, and the nature of the residue should play a minor
role [21,26,27]. Therefore, different stereoisomers can
reproduce different types of conformational elements
of the peptide backbone, as various b-turns, c-turns,
or a-helical structures.
However, despite the constrained structure, these
molecules often exhibit a remarkable degree of residual
flexibility, especially in the presence of a Gly [21,26].
In principle, the occurrence of a conformational equi-
librium between different structures does not prohibit
efficient receptor binding, allowing the peptide a cer-
tain facility to adapt to the receptor cavity. This con-
formational freedom could be responsible for the
possibility that compound 3 fitted the receptor by
adopting alternative backbone conformations.
In order to gain further information about the bio-
logically active structure, we have synthesized a new
set of CPPs having the same sequence YpwF as com-
pound 3 and a different amino acid, Xaa, in position 5
in place of Gly, with different structure and length
(Fig. 2). We introduced longer, flexible connectors
between Tyr1 and Phe4, Xaa5 = b-Ala (compound 4)
and Xaa5 = c-aminobutyric acid (compound 5),
which in principle should confer the peptide a higher
conformational freedom, or conversely, we introduced
conformationally restraining residues, Xaa5 = a-amino-
isobutyric acid, Aib (compound 6), Xaa5 = d-Pro
(compound 7), and Xaa5 = l-Pro (compound 8). In
particular, Aib in an oligopeptide predominantly sam-
ples the right-handed and left-handed 310-helix region,
whereas the presence of l-Pro or d-Pro generally
favors the formation of turns or inverse turns
[21,26,35].
The CPPs of general sequence c[YpwFXaa] have
been prepared from the corresponding linear pentapep-
tide precursors, obtained in turn by standard solid
phase peptide synthesis, using a Wang resin, Fmoc-
protected amino acids, and N,N¢-dicyclohexylcarbodii-
mide ⁄HOBt as coupling agents [36]. The cleavage from
the resin was obtained by treatment with trifluoroacetic
Table 1. Synthesis, analytical characterization and receptor affinities (means ± SE of three experiments) of DAMGO and compounds 3–8.
Compound Sequence Yield (%)a Purity (%) MS ⁄ calculated [M + 1] Ki (M) IC50 (M)
DAMGO YaG-NMeF-Glyol – – – 1.6 ± 0.3 · 10)9 9.9 ± 0.6 · 10)9
3 c[YpwFG] 62 96 651.2 ⁄ 651.1 3.4 ± 0.7 · 10)8 4.4 ± 0.6 · 10)8
4 c[YpwF-bAla] 58 93 665.3 ⁄ 665.3 6.1 ± 0.5 · 10)6 1.6 ± 0.2 · 10)5
5 c[YpwF-GABA] 64 93 679.5 ⁄ 679.3 3.2 ± 0.4 · 10)6 8.4 ± 0.8 · 10)6
6 c[YpwF-Aib] 55 95 679.2 ⁄ 679.3 2.9 ± 0.3 · 10)6 7.6 ± 0.7 · 10)6
7 c[YpwFp] 53 96 691.6 ⁄ 691.3 3.2 ± 0.2 · 10)5 8.3 ± 0.9 · 10)5
8 c[YpwFP] 59 95 691.5 ⁄ 691.3 7.2 ± 0.5 · 10)7 9.0 ± 0.4 · 10)7
a Yield of the cyclization step after purification.
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acid in the presence of scavengers, and the resulting lin-
ear peptides were subjected to in-solution cyclization
with diphenylphosphorylazide (DPPA). The crude
CPPs were purified by flash chromatography over silica
gel, and using semipreparative RP-HPLC, and were
characterized by analytical HPLC, ES MS, and
1H-NMR. Yields after purification, purities and mass
characterizations are reported in Table 1.
To determine the affinities towards the MORs, we
performed displacement binding assays for com-
pounds 3–8 and for the potent MOR-selective agonist
DAMGO (H-Tyr-d-Ala-Gly-N-MePhe-glyol) as a ref-
erence compound. The peptides were incubated with
rat brain membrane homogenates containing the recep-
tors, using [3H]DAMGO as a l-specific radioligand
[20] The Ki and IC50 values are reported in Table 1. In
general, the peptides showed a concentration-depen-
dent displacement of [3H]DAMGO. Most of the pep-
tides showed scarce receptor affinities; in particular,
the introduction of longer, flexible amino acid spacers
in compounds 4 and 5 led to a decrease of the Ki and
IC50 values with respect to compound 3. Apparently, a
longer distance between the strategic pharmacophores
of Tyr1 and Phe4 is not optimal for binding the
receptor.
On the other hand, the introduction of spacers capa-
ble of reducing cyclopeptide flexibility is expected to
influence OR affinities, depending on the precise con-
formation adopted by the whole molecule, albeit an
improper size, nature, etc. of the conformation-
controlling residue could obstruct efficient binding.
Interestingly, whereas the introduction of Aib and
d-Pro gave compouns 6 and 7, respectively, with a
lower receptor affinity, the introduction of l-Pro gave
compound 8, which retained a moderate ability to bind
the receptor, with Ki and IC50 in the 10
)7 range
(Table 1).
Conformational analysis of compounds 3, 7 and 8
in solution
Compound 3, c[YpwFG], can be attributed an lddll
or an lddld chirality, as Gly5 can act both as an
l-residue and a d-residue. Therefore, we decided to
investigate and compare the in-solution conformational
features of compound 3, compound 7, c[YpwFp],
which shows lddld chirality, and compound 8,
c[YpwFP], having lddll chirality, by spectroscopic
and molecular dynamics (MD) analyses.
In spite of the moderate or scarce MOR affinities,
the comparison of the in-solution structures of com-
pound 3 with the structure of compound 7, which is
very poorly active towards the MOR, and com-
pound 8, which maintained some activity, being almost
two orders of magnitude more active than the latter,
could furnish useful clues on the biologically active
structure of this class of atypical peptides. Also, the
introduction of further conformational constraints in
compounds 7 and 8 by changing the Gly to d-Pro or
l-Pro should reduce the risk of ambiguous structures.
We could not perform experiments in water, because
the peptides were practically unsoluble. Many peptides
or peptidomimetics of interest described in the litera-
ture are not highly soluble in water, and have been
studied experimentally in organic polar environments,
in particular dimethylsulfoxide (for a leading reference
on the use of dimethylsulfoxide as a biomimetic med-
ium for the NMR of opioid peptides, see [37]).
Accordingly, the NMR experiments on the lipophilic
cyclopeptides were conducted using standard tech-
niques at 400 MHz in dimethylsulfoxide-d6.
For compound 3, 1H-NMR revealed a single set of
resonances, suggesting conformational homogeneity or
a fast equilibrium between conformers [21,26]. Variable
temperature (VT)-1H-NMR experiments (supplemen-
Fig. 2. Structures of the cyclopeptides
c[YpwFXaa].
The atypical opioid agonist c[YpwFG] L. Gentilucci et al.
2318 FEBS Journal 275 (2008) 2315–2337 ª 2008 The Authors Journal compilation ª 2008 FEBS
tary Table S1) in dimethylsulfoxide-d6 gave the follow-
ing Dd ⁄ Dt values (p.p.b. ⁄K): TyrNH, )4.8; PheNH,
)5.3; GlyNH, )1.4; d-TrpNH, )1.5. As there is a cer-
tain difference between the temperature coefficients, it
is possible to hypothesize a conformational preference
for a conformation in which GlyNH and d-TrpNH
are involved in hydrogen bonds (Dd ⁄ Dt of GlyNH and
d-TrpNH < 2 p.p.b. ⁄K) [38].
Finally, 2D-ROESY in dimethylsulfoxide-d6 fur-
nished, apart from the obvious correlations, several
diagnostic cross-peaks. The absence of Hai–Hai + 1
cross-peaks was used to exclude the presence of cis
peptide bonds. The observation of strong ROESY
cross-peaks between Tyr1Ha and both d-Pro2Hd was
also used to infer a trans Tyr1–d-Pro2 amide bond.
The data derived from NMR were analyzed by
restrained MD, using nongeminal interproton distances
as constraints, and structures were optimized with the
AMBER force field [39]. The low-energy conformation
with the lowest deviations from NMR data is shown
in Fig. 3. This structure does not confirm the occur-
rence of explicit hydrogen bonds, probably because of
the occurrence of a fast equilibrium between different
geometries, whose average in the NMR time scale
gives the structure determined by ROESY analysis
[21,23]. Concerning the orientations of the side chains,
ROESY data accounted for a trans, g+, and g) orien-
tation of Tyr, d-Trp, and Phe, respectively.
To investigate the inherent flexibility of the cyclo-
peptide backbone [21], we performed a 5.0 ns unre-
strained MD simulation in explicit water. During the
simulations, the cyclopeptide oscillated from a pre-
ferred conformation A, matching the VT-NMR tem-
perature coefficients (Fig. 4, supplementary Table S1),
characterized by a type II b-turn centered on Tyr1-
d-Pro2, and an inverse c-turn centered on Phe4, to a
secondary conformation B showing an inverse type I
b-turn centered on d-Pro2-d-Trp3, and a c-turn on
Gly5 (Fig. 4). During the simulations, the more fre-
quently populated rotamers observed for Tyr, d-Trp
and Phe were in agreement with ROESY data.
The conformational analysis of compound 7,
c[YpwFp], was performed in a similar way as for
compound 3. The structural data obtained from NMR
analysis reproduced most of the features of com-
pound 3. 1H-NMR revealed also the presence of a
extra set of small signals in the NH region, indicating
a small population (< 5%) of conformers in slow
equilibrium with the main species. This secondary
population very likely corresponds to conformers
containing at least one cis peptide bond preceding
Pro, in agreement with other CPPs containing two
Pro residues reported in the literature [26]. Because of
the scarce intensity of the secondary set of signals, the
conformational analysis was conducted only on the
predominant conformer.
Fig. 3. Minimized conformation of compound 3 calculated by
restrained MD with the lowest internal energy and the least num-
ber of violations of ROESY data.
A B
Fig. 4. Conformations A (left) and B (right) of compound 3 observed from unrestrained MD simulations in explicit water.
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The data derived from 2D-ROESY analysis, indicat-
ing an all-trans disposition of the x-bonds, were uti-
lized for performing restrained MD, and the structures
were optimized with the AMBER force field. The rep-
resentative conformation with the lowest energy and
the least violations of restraints is shown in Fig. 5.
This structure shows an explicit hydrogen bond
between Tyr1CO and Phe4NH, and a conformation in
which the residues d-Pro2-d-Trp3 occupy positions
i + 1 and i + 2 of a inverse type I b-turn, whereas
Gly5 occupies position i + 1 of a c-turn. The involve-
ment of PheNH in a hydrogen bond could not be
deduced on the basis of simple VT-NMR analysis.
The structure of compound 7 very closely resembles
the structure of compound 3B (Fig. 4). The mirror
image of the conformation of compound 7, c[YpwFp],
which is characterized by lddld chirality, is perfectly
compatible with that reported in the literature for
c[GPfAP] and other CPPs [26,40] in solution, charac-
terized by a type I b-turn on Pro2-d-Phe3, and a
inverse c-turn on Pro5. The latter peptide has dlldl
chirality, opposite to that of compound 7, and con-
tains two Pro residues in the same positions, 2 and 5,
as in compound 7, and Gly1, serving as a d-residue
[26].
The unrestrained MD simulation in explicit water
confirmed the strong stability of the conformation. At
intervals, the simulation revealed also the presence of a
c-turn on d-Pro5. The low Dd ⁄ Dt value observed for
d-TrpNH could, in principle, be causedby a popula-
tion of conformers showing an alternative hydrogen-
bonded structure. The same CPP model, c[GPfAP],
has also been reported to adopt a inverse type II
b-turn centered on Gly1-Pro2 and a c-turn centered on
Ala4 in the crystal state [26]. However, for the com-
pound 7, no trace of any turn centered on Gly1-Pro2
was observed during the time selected for the simu-
lation.
Finally, we analyzed the conformation of com-
pound 8, c[YpwFP]. As for compound 7, 1H-NMR in
dimethylsulfoxide-d6 revealed a more abundant and a
largely minor set of resonances, which was neglected.
Concerning the 2D-ROESY analysis in dimethylsulfox-
ide-d6, the presence of a clear cross-peak of type Hai–
Hai + 1 between Phe4Ha and Pro5Ha was considered
to be indicative of a cis Phe4-Pro5 x-bond. The other
Pro-preceding peptide bond was considered to be
trans, because of the presence of strong cross-peaks
between Tyr1Ha and both d-Pro2Hd. The interproton
distances deduced from ROESY analysis were utilized
as constraints for performing restrained MD simula-
tions. The large majority of the calculated structures of
compound 8 did not show any significant violation of
the restraints associated with backbone protons, and
were well ordered. The representative structure
reported in Fig. 6 is consistent with an inverse type I
b-turn centered on d-Pro2-d-Trp3. VT-1H-NMR anal-
ysis in dimethylsulfoxide-d6 confirmed the involvement
of PheNH in a very strong hydrogen bond (supple-
mentary Table S1).
Finally, the unrestrained MD simulation performed
in explicit water confirmed the extreme stability of the
conformation.
Fig. 5. Representative minimized conformation of compound 7 cal-
culated by restrained MD with the lowest internal energy and the
least violations of restraints.
Fig. 6. Representative conformations of compound 8 calculated by
restrained MD and minimized with the lowest internal energy and
the least violations of restraints (no significant violations of the
restraints associated with backbone protons).
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Molecular docking
The potential receptor-binding modes of the CPPs
have been analyzed by molecular docking. As reported
in the literature, it is manifest that for most opioid
ligands the construction of ligand–receptor complex
models began with the assumption that the protonated
amine interacted electrostatically with Asp147 in trans-
membrane helix (TMH) III (Fig. 7) [28,41,42]. In sev-
eral cases, ligands have been manually docked into the
receptor cavity in order to place the protonated amine
close to the conserved Asp. Compound 3 does not
contain any ionic functionalities; therefore, an alterna-
tive approach must be undertaken. The main binding
force towards the receptor would comprise hydropho-
bic and hydrogen-bonding interactions.
Because of the absence of a leading interaction, the
docking process was performed by autodock [30],
because it is a truly exhaustive docking program that
explores the full pose and conformational space of the
protein–ligand complex using a very fine grid. Follow-
ing the creation of an appropriate interaction model of
compound 3 (the most active analog), using the ‘blind
docking’ approach [31,32], compound 3 and its ana-
logs were docked into the approximate binding site
previously found using a finer grid (‘refined docking’),
and the resulting orientations were then equilibrated
by MD.
The conformations resulting from the ‘blind dock-
ing’ run were clustered, and most of them (up to 91%
of the docking solutions) were found to be located in
the channel pore between TMH III, TMH V,
TMH VI, TMH VII, and the extracellular loop (EL)-
2. The residues belonging to the binding site within
3 Å from the ligand are those corresponding to
Tyr148, Met151 and Phe152 (TMH III), Lys233 and
Phe237 (TMH V), Ile296, Val300, Lys303 and Thr307
(TMH VI), Trp318 and Ile322 (TMH VII) and
Thr218, Leu219 and Phe221 (EL-2) of MOR.
The location of this binding site was then used as
the starting point for the second docking run. In this
case, the use of a finer grid resolution allowed a supe-
rior evaluation of ligand–receptor interactions, with
lower (improved) docked energies being obtained with
respect to the previous step. The cyclopeptide confor-
mations resulting from this ‘refined docking’ study
were clustered and, after a visual inspection of the
docking results, the solutions could be divided into
two main orientations, orientation 1 and orientation 2,
based on the position of the ligand inside the binding
pocket and on the residues that were within 5 Å of the
ligand (for comparative side ⁄ top views of orientation 1
(A–C) and orientation 2 (D–F) of the different CPPs,
see also supplementary Fig. S5). In the following sec-
tions a detailed discussion to define the best orienta-
tion in terms of ligand-receptor binding efficacy is
presented.
Orientation 1
The location of compound 3 in this orientation shows
the Tyr1 group pointing towards a hydrophobic
pocket composed mainly of the aromatic residues
Tyr148, Phe237, Phe241 and Trp293 (Fig. 8A). By
Fig. 7. Cartoon representation of the TMHs
and ELs of MOR, top view from the
extracellular surface, colored by secondary
structure succession, and prepared using
PYMOL [42].
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comparison with Fig. 4, it appears that this disposition
within the receptor cavity seems to be similar to the
preferred conformation adopted in solution. The
ligand–receptor complex is stabilized by four hydrogen
bonds: two between the backbone oxygen of Gly5 and
Od1 and Od2Asp147 (2.90 and 2.78 Å respectively), the
only residue from THM III within 5 Å of com-
pound 3, one between Oc1 of Thr218 (EL-2) and the
backbone oxygen of Phe4 (2.94 Å), and one between
the hydroxyl oxygen of the Tyr1 group and OAla240
(TMH V) of 2.66 Å.
The close proximity of Tyr1 to THM VI would
allow hydrogen bonds to be formed here with the
backbone carbonyl, which may stabilize the position of
this group. As stated above, in this orientation, com-
pound 3 is stabilized also by many ‘stacking’ or p–p
interactions between the aromatic moieties of Tyr1 and
Phe4 and the side chains of Phe237, Phe241 and
Trp293 (Trp1), Trp218 and Phe221 (Phe4). Trp3 is
involved in a cation–p interaction with Lys303
(TMH VI), whereas the other positive residue within
5 Å of the ligand (Lys233, belonging to TMH V) does
not show any evident interaction with compound 3.
The docking results for the other cyclopeptides (with
the exception of compound 8, see below) give rise to a
binding conformation very close to that obtained
for compound 3 (Fig. 8; see supplementary Fig. S5).
Compounds 4–6 show the poorer binding score values,
a result that can be related to an inadequate interac-
tion with the binding site. In this orientation, com-
pound 4 is characterized by a shift (rotation) of Tyr1
away from TMH V and TMH VI, giving rise to the
breaking of the hydrogen bonds with Ala240 and
Asp147, and by the presence of only one lengthened
hydrogen bond, between OPhe4 and Oc1Thr218 (EL-2)
of 3.52 Å. Tyr1 is always inserted inside the aromatic
A B C
D E F
Fig. 8. Side views of compounds 3–8 in orientation 1 [ordered from (A) (compound 3) to (F) (compound 8) and rendered as sticks] docked
into the binding site of MOR using AUTODOCK, except for compound 8, which was manually docked (see text). The MOR is shown in cartoon
representation and colored by secondary structure succession, the residues within 5 Å of compounds 3–8 are shown as wireframe, and
hydrogen bonds are shown as yellow dashed lines. All of the figures were prepared using PYMOL [42].
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cluster and Phe4 is stabilized by a p–p interaction with
Trp318, but Trp3 does not show any cation–p interac-
tion with Lys303.
In compounds 5 and 6, HOTyr1 is capable of inter-
acting again with OAla240 (2.52 and 2.81 Å, respec-
tively). These structures are stabilized also by
hydrogen bonds between NGABA5 and OCys217 (for
compound 5, 2.20 Å) and between OPhe4 of com-
pound 6 and Oc1Thr218 of 2.42 Å, but the increasing
size of the Xaa5 residue still prevents the interaction
with Asp147. In compound 7, where Xaa5 is a d-Pro
residue, the interaction with Asp147 is restored, by
means of the carbonyl oxygen of d-Pro5 (2.20 Å), and
supported by a hydrogen bond between NTyr1 and
Oc1Thr218 (3.30 Å). Trp3 is again involved in a cat-
ion–p interaction with Lys303 (TMH VI), and Tyr1 is
now stabilized by two p–p interactions with the aro-
matic side chains of Phe237 and Trp293.
For compound 8, the one showing the second-best
affinity (Table 1), none of the docking solutions can be
clustered in an orientation comparable to orienta-
tion 1, a result at first attributable to the excessive ste-
ric hindrance of the Pro5 residue. This observation is
not completely surprising. For compounds 3 and 7, the
structures in orientation 1 (Fig. 8A,E) roughly corre-
spond to the preferred conformations in solution,
whereas compound 8 in solution shows a quite differ-
ent shape from that adopted by the other peptides.
Concerning compounds 4 and 5, the introduction of
longer, flexible Xaa5 spacers is expected to increase the
overall conformational freedom and the adaptability
to the receptor-binding pocket.
Consequently, compound 8 was manually docked
inside the MOR binding pocket, using the orientation
of compound 3 as a template. This results in a confor-
mation characterized by the presence of three hydro-
gen bonds between Oc1Thr218 and NTyr1, OPhe4 and
OPro5 (of 2.77, 2.96 and 3.26 Å, respectively) and by
two p–p interactions between Tyr1 and Phe237, and
Trp3 and Phe221. Tyr1 is always inserted inside the
aromatic cluster, but lacks the hydrogen bonds with
Ala240 and Asp147 (Fig. 8F). The binding site is com-
pleted by Asp216, Val300, His319 and Ile322, which
are located within 3.5 Å of compound 3, although no
particular interactions are implicated between these
residues and the ligand. The complete amino acid com-
position of the binding site is reported in supplemen-
tary Tables S5–S11.
Orientation 2
In this orientation, the one showing the best binding
energy scores for all the studied peptides, compound 3
is located in a cavity-like region inside the channel
pore (Fig. 9A), reversed as compared to orientation 1,
and shifted approximately 3.3 Å away from TMH VI,
which brings Ala240 (TMH V) and His297 (TMH VI)
to a position far away from the ligand. The reposition-
ing of compound 3 also means that EL-3 is now within
5 Å of the ligand.
The overall shape of the receptor-bound structure of
compound 3 in orientation 2 strongly differs from that
in solution (Fig. 4), also in terms of backbone confor-
mation. Compound 3 is directed towards the bottom
of the binding site by its d-Trp3 group and stabilized
by the formation of six hydrogen bonds: a bidentate
hydrogen bond between Od1 and Od2 of Asp147
(TMH III) and the nitrogen atom of the d-Trp3 indole
ring (3.15 and 3.06 Å, respectively), two contacts
between the backbone carbonyl oxygen of the Tyr1
group and Oe2Glu229 (TMH V, 3.22 Å) and OThr220
of 3.30 Å, and the last bidentate hydrogen bond
between the Oe1 and Oe2Glu310 (EL-3) and the OH-
Tyr1 of compound 3 (3.04 and 3.38 Å, respectively).
In this orientation, Tyr1 and Phe4 are surrounded by
Phe221 and Trp318, and the d-Trp3 is now located
inside the hydrophobic pocket that in orientation 1
was occupied by Tyr1 and composed mainly of the
aromatic residues Tyr148, Phe152 and Phe237.
Thr218, Leu219, Lys233, Lys303, Thr307 and
His319 are located within 3.5 Å of the CPPs and com-
plete the binding site walls, although no particular
interactions are implicated between these residues and
the ligand. Again, the complete amino acid composi-
tion of the binding site is reported in supplementary
Tables S5–S11.
The docking results for the other CPPs give rise to a
binding mode similar to that obtained for compound 3
(Fig. 9 and supplementary Fig. S5). The analysis of
the docking solutions for compound 4 shows the
absence of contacts with both Asp147 and Glu310,
and the presence of only one hydrogen bond between
the carbonylic oxygen of d-Pro2 and Oc1Thr218 of
2.69 Å, a situation common also to compound 5, sta-
bilized by the formation of two hydrogen bonds
between Oc1Thr218 and OPro2 and NPhe4 of 3.26 and
3.45 Å, respectively. This behavior is partially verifi-
able in compounds 6 and 7 where the hydrogen bond
with Asp147 is still absent but there is re-formation of
the contact between HOTyr1 and Oe2Glu310 with dis-
tances of 2.63 and 2.69 Å (for compounds 6 and 7,
respectively). In compound 7, the conformation is also
stabilized by a cation–p interaction between Tyr1 and
Lys303.
The binding mode observed for compound 3 in
orientation 2 is completely restored in compound 8,
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with the formation of three out of five hydrogen
bonds: one between Od2Asp147 and the nitrogen atom
of the d-Trp3 indole ring of 3.34 Å, one between
NPhe4 and Oc1Thr218 of 3.23 Å, and one between
Oe2Glu310 and OHTyr1 of compound 8 (3.23 Å). In
this orientation, d-Trp3 of compound 8 is surrounded
by Phe237 and Trp293, and Tyr1 is involved in a
cation–p interaction with Lys303.
Hybrid QM ⁄ MM induced fit
The two main orientations of all the peptides were
then further analyzed through hybrid QM ⁄MM geom-
etry optimization [33,34]. There are several reasons for
combining docking techniques with other computa-
tional methods: estimation of the quality of the scoring
functions, re-ranking of the structures generated by
docking, simulation of the structural adaptations that
occur in a receptor upon ligand binding, a more
detailed description of the binding mode of the ligand,
and, in the case of QM methods, a complete descrip-
tion of reaction mechanisms and electronic properties.
Hybrid QM ⁄MM methods have become a standard
tool for the characterization of complex molecular sys-
tems. The basic idea of these methods is to treat that
part of the system that undergoes the most important
electronic changes upon binding a substrate quantum
mechanically, and the rest of the system by traditional
molecular mechanics.
The protein environment is influenced by a ligand
bound to the binding site (‘induced fit’), and a
QM ⁄MM optimization of the resulting complexes
gives a more accurate description of the electronic
and steric properties of the ligand. As QM calcula-
tions on whole protein systems are computationally
very demanding, we chose a QM ⁄MM approach for
A B C
D E F
Fig. 9. Side view of componds 3–8 in orientation 2 [ordered from (A) (compound 3) to (F) (compound 8) and rendered as sticks] docked into
the binding site of MOR using AUTODOCK. The MOR is shown in cartoon representation and colored by secondary structure succession, the
residues within 5 Å of compounds 3–8 are shown as wireframe, and hydrogen bonds are shown as yellow dashed lines. All of the figures
were prepared using PYMOL [42].
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the optimization of the two solutions obtained by
docking, using the program package gaussian 03
[43]. First, the relevant binding conformations of the
MOR–substrate system resulting from the molecular
docking runs were equilibrated for 1.2 ns by MD, at
constant temperature and pressure in a periodic cubic
box, using the TIP3P model for water molecules. The
systems were subsequently optimized using the com-
bined QM ⁄MM approach, with a flexible receptor
environment that allows the simulation of the adapta-
tion of the receptor upon ligand binding. This proce-
dure give rise to a rearrangement of the residues
forming the binding site around the ligand (‘induced
fit’), leading to the situation shown in Fig. 10 for
compounds 3, 7 and 8 in both orientations 1 and 2
(results for the remaining CPPs are not shown; see
also supplementary Tables S7–S9).
The compound 3 binding site optimization lead to a
small difference in the residue geometry with respect to
the starting conditions, with all-atoms rmsd values of
1.08 and 1.21 Å for orientations 1 and 2, respectively.
The numbers of hydrogen bonds and residues that
make contact with compound 3 is almost unaffected:
the ligand in orientation 2 moves towards TMH III
and EL-2, making new contacts with residues belong-
ing to TMH VI. Phe221, Trp318 and His319 remain
almost unaffected by the binding with compound 3,
whereas Asp147 and Glu310 move towards d-Trp3
and Tyr1, respectively, to improve the hydrogen bond
geometry.
The most significant variation in orientation 2
involves the Trp293 residue of TMH VI, which reori-
ents its indole side chain, leading to a better p–p inter-
action. The same effect can be observed for Phe237
A B C
D E F
Fig. 10. Details of the QM region used in the QM ⁄ MM optimization of the complex formed between the MOR and the bioactive conforma-
tions of compounds 3, 7 and 8 in orientation 1 (A–C) and orientation 2 (D–F). Yellow sticks: MOR residue positions after the QM ⁄ MM opti-
mization results. Blue sticks: MOR residues included in the QM part in their initial conformation. The ligands after the QM ⁄ MM optimization
are represented by sticks (CPK color) and enclosed by their solvent accessible surface (SAS).
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and Phe241, but in these cases the flip of the aromatic
side chains is not so great as for Trp293.
The QM ⁄MM binding site optimization of com-
pound 7 shows a pattern of residue movements super-
imposable on those observed for compound 3, leading
to the smallest difference in the residue geometry with
respect to the starting conditions, with all-atoms rmsd
values of 0.85 and 1.12 Å for orientations 1 and 2,
respectively. In orientation 1, the movements of the
binding site residues due to the ligand binding are
mainly represented by a series of modest rotations of
the Tyr148, Phe237, Phe241 and Trp293 lateral chains,
in order to surround Tyr1. Asp147 remains almost
unchanged by the ligand binding, and the positively
charged residues Lys233 and Lys303 point towards
d-Trp3, whereas Ile322 and His297 move far away
from the ligand to lower the steric hindrance with
d-Pro5 and Tyr1, respectively. In orientation 2, the
binding site require a smaller amount of movement to
adapt its structure to compound 7. In this case, the
Lys residues, Trp293 and Asp147 do not move from
their initial positions, whereas Glu310 moves towards
Tyr1 to improve the hydrogen bond geometry.
As stated above, the analysis of compound 8 in ori-
entation 1 started from the manually docked structure
because of the absence of a solution matching this ori-
entation in the automated docking run, and this
behavior can be explained by taking into account the
results obtained in the QM ⁄MM run. The binding of
compound 8 in orientation 1 leads to extensive varia-
tions in the 3D structure of the binding site with
respect to the starting conditions (with an all-atoms
rmsd of 1.21 Å), in particular near the Pro5 residue,
with a wide movement of the Asp147, Tyr148, Trp293
and Ala323 lateral chains. In orientation 2, com-
pound 8 shows the same behavior as compound 3, but
with more important variations in the zone near
Trp293, composed mainly of Phe237 and Phe241, and
a small reorientation of the Trp293 indole lateral
chain, suggesting less activation of the receptor with
respect to compound 3.
Afterwards, the residue movements resulting from
the induced fit analysis lead, for compound 3, to a cav-
ity geometry characterized by values of the exposed
area of  770 Å2 and  780 Å2 for orientations 1 and
2 respectively, but with a smaller contact area for ori-
entation 2 with respect to orientation 1 ( 597 Å2 and
 537 Å2 for orientations 1 and 2, respectively). This
behavior is common to all of the studied CPPs, leading
to a smaller deformation of the binding site and
Fig. 11. Comparison of the secondary struc-
ture elements determined for compounds 3,
7 and 8, and for the model CPPs, com-
pounds 9 and 10.
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then to greater stability of the cyclopeptide–receptor
complex.
Discussion
CPPs are expected to be relatively conformationally
rigid. However, despite the constrained structure, CPPs
generally exhibit a remarkable degree of residual flexi-
bility. In the previous section, MD simulations indi-
cated that the opioid CPP agonist compound 3 in
solution can adopt a couple of different b ⁄ c-turn con-
formations stabilized by alternative hydrogen bonds,
whereas compounds 7 and 8 show more rigid struc-
tures, characterized by a single main conformation.
Interestingly, whereas lddld compound 7 adopts an
all-trans x-bond conformation, in agreement with simi-
lar CPPs reported in the literature, the unprecedented
lddll compound 8 adopts a one-cis-four-trans x-bond
conformation, the cis peptide bond being the one
preceding Pro5 (Fig. 11).
It is generally accepted that the overall conformation
of CPPs depends, for the most part, on the stereo-
chemistry array. The structure of compounds 3 (lddll
or lddld), 7 (lddld), and 8 (lddll) can be tenta-
tively compared to that of lddll or lddld cyclopen-
taalanine models [27]. Therefore, compounds 3, 7 and
8 can be compared either to the model c[AaaAA],
which exhibits lddll chirality, or to the mirror image
of the model c[aAAaA] (compound 9) as well as of the
structurally related avb3-integrin inhibitor c[fVRGD]
(generally reported as c[RGDfV]) [27], both of which
show dlldl chirality, the opposite of lddld (Fig. 11).
The structure of the lddll model c[AaaAA] shows
a well-defined type II b-turn on Ala1-d-Ala2. On the
other hand, the diastereomeric lddld model c[aAAaA]
(compound 9) still maintains a type II inverse b-turn
on d-Ala1-Ala2, and also a c-turn on d-Ala4. As a
consequence, conformation A of compound 3 can be
easily rationalized.
However, Pro-containing cyclopeptides usually man-
ifest specific structural features with respect to the
other cyclopeptides, mainly due to the increased prob-
ability of showing a cis conformation of the x-bond
preceding Pro, and the strong tendency to stabilize
turn structures.
In particular, Pro tends to occupy the i + 1 position
of a b-turn or of a c-turn. Indeed, dlldl Pro-contain-
ing CPPs such as c[GPAfP] [26] (compound 10),
d-Gly(Set)-PFaV [40], c[GPSaP], c[GPAaP] or
c[fPGaP] showed all-trans peptide bond structures
characterized by a preference for a type I ⁄ type II
b-turn centered on the residues in positions 2 and 3,
accompanied by a inverse c-turn on the residue in
position 5. Apparently, the presence of a Pro in posi-
tion 2 of compound 3 is responsible for the occurrence
of the second conformation, conformation B (Fig. 11).
Accordingly, the mirror image of the conformation
of the two-Pro-containing compound 7 determined by
restrained MD perfectly matches the conformational
aspects of the above described dlldl CPP models
containing two Pro residues (see also Results).
In contrast, the chirality sequence and conformation
of compound 8 do not match other two-Pro-contain-
ing CPPs reported in the literature. In general, the
competition between structures having a cis Xaa-Pro
peptide bond versus b-turn or c-turn structures in
which the Xaa-Pro peptide bond must necessarily
adopt a trans conformation mainly depends on the chi-
rality of the other residues, rather than on their nature.
For instance, it has been documented that the intro-
duction of an l-Ala in position 1 of c[GPGaP] destabi-
lized the original conformation, giving a mixture of an
all-trans and a one-cis form in the Ala–Pro x-bond
[26]. In a similar way, the introduction of an l-Ala4 in
c[GPfaP] in place of the d-residue lead to the coexis-
tence in solution of four different structures containing
all possible combinations of trans ⁄ cis x-bonds preced-
ing both Pro2 and Pro5 (cis ⁄ cis, trans ⁄ trans, cis ⁄ trans,
trans ⁄ cis) [26]. Remarkably, compound 8 shows a sin-
gle one-cis-four-trans x-bond conformation, instead of
a mixture of different cis ⁄ trans structures.
Despite the presence of distinct secondary structure
elements, both conformations 3A and 3B show rather
similar display of aromatic side chains (Fig. 4), the
main difference being the distance between Tyr1 and
Phe4 side chains. In particular, conformation A
observed in solution for compound 3 is in agreement
with the structural requirements reported in the litera-
ture for good activity and selectivity towards MORs.
Conformational analysis of EM-1 [44], morphiceptin
[45], enkephalins [46] and their derivatives [28,47–51]
have established that a trans vTyr1 angle, and a rela-
tively large separation (about 11–13 Å) of the Tyr phe-
nolic ring with a second aromatic pharmacophore, are
necessary for optimal interaction with MORs [52]. In
addition, a g) orientation has been recommended for
vTrp3 [47], whereas a preferential g) conformation of
Phe4 has been hypothesized on the basis of the good
receptor affinity shown by endomorphin analogs con-
taining a (2S,3S)-b-MePhe in position 4 [53].
Concerning compound 3, in conformation A the
aromatic side chains of Tyr1 and Phe4 are about 12 Å
from each other, and their v angles are trans and g),
whereas the g+ orientation observed for d-Trp3 is
compatible with the reversal of the absolute configura-
tion with respect to EM-1. In essence, compound 3A
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seems to be almost superimposable on that of the
potent MOR agonist JOM-6 (Fig. 12), whose interac-
tion with OR has been the subject of intense investiga-
tion [50,51]. In particular, the key interaction between
the ligand and the receptor was determined to be the
ionic interaction involving the ligand’s TyrNH and
Asp147 of TMH III, as reported for several other
opioid agonists [28,41].
The structural similarity seems to suggest that the
two compounds could interact with the MOR in a sim-
ilar way, the absence of ionic interactions being
responsible for the lower affinity of compound 3 with
respect to JOM-6 (KI = 0.17 nm [50,51]). However,
the correlation between the diverse biological activities
of compounds 3, 7, and 8, and their in-solution struc-
tures, discourages this assumption. Indeed, it is evident
that whereas the pharmacophores of the two com-
pounds are almost superimposable, the CPP backbone
does not superimpose at all. In principle, the observed
flexibility shown by compound 3 could account for the
possibility of a CPP–receptor fit with a distorted con-
formation. However, the moderate receptor affinity
shown by the less flexible compound 8, which in solu-
tion adopts a different 3D structure with respect to
compound 3, requires the formulation of a different
ligand–receptor interaction model.
As a consequence, the interactions between the CPPs
and MOR have been investigated by molecular dock-
ing. The computations indicated that, in general, the
CPPs can fit the receptor by adopting two different,
opposite dispositions. The first model is similar to the
model described for JOM-6, and shows a peptide dis-
position within the receptor cavity, orientation 1, very
similar to the preferred conformation adopted in solu-
tion (Figs 8 and 12), whereas in the second model, the
CPPs are located in the receptor with a reversed dispo-
sition, or orientation 2 (Fig. 9).
A comparison between orientations 1 and 2 of the
most active cyclopeptide, compound 3, reveals a differ-
ent overlap to that of JOM-6 (Fig. 13). The aromatic
ring of the Phe4 residues of compound 3 is completely
superimposable on that of Phe3 of JOM-6, especially
that of orientation 2. Orientation 1 is able to obtain
an excellent superimposition of Tyr1, whereas orienta-
tion 2 is reversed, replacing Tyr1 with d-Trp3. But the
main difference is evident when considering the super-
position of the backbones: in orientation 2, the back-
bone is located in the same position with respect to
that of JOM-6, whereas the backbone in orientation 1
is shifted by about 5 Å towards the bottom of the
receptor cavity, leading to greater steric hindrance. For
all the studied peptides, the shift of the cyclic back-
bone can also be related to the small difference in the
docking score, giving rise to a situation where orienta-
tion 2 is favored over orientation 1.
These differences between the two orientations must
be analyzed considering that: (a) the great majority of
conformers were found in orientation 2; and (b) the
binding energy of the conformations found for the
first orientation were always near those found for the
second one (the one showing the best docking score).
As the lack of flexibility in the protein may influence
the binding modes of the ligands, and the affinities
and orientations may vary significantly from one
solution to another, these results should be considered
with care. In particular, the small difference in the
docking score between the two orientations of the
CPPs gives rise to a difficulty in the prediction of
which one is the best orientation. It is worth noting
that the binding site was found without imposing any
Fig. 12. Comparison of the receptor-bound structure of JOM-6 with the in-solution average structure of compound 3.
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constraint and in the absence of water molecules in
the docking process.
Interestingly, whereas compound 3 and the analogs
compounds 4–7 can fit the receptor in both orienta-
tions, compound 8 shows an exclusive preference for
the second, reversed orientation 2. The docked struc-
ture of compound 8 in orientation 2 shows some struc-
tural differences in the Pro5 region with respect to the
in-solution structure. In a similar way, the in-solution
conformation of compound 3 has to be modified in
order for it to fit the receptor. Compound 8 has a
comparatively higher conformational rigidity; there-
fore, the modification of the in-solution conformation
to fit the receptor has some consequences in terms of
biological activity, and indeed compound 8 shows a
lower activity than compound 3.
The analysis of the correlation coefficients obtained
between the calculated docking energies and the Ki or
IC50 values demonstrates the better predictive power
of orientation 2 with respect to orientation 1. This
finding is confirmed by looking at the excellent statisti-
cal parameters obtained for the linear regression of
DGdock versus DGexp for orientation 2 (Fig. 14).
It is important to emphasize that orientation 2 is
characterized by several intense interactions, with
Asp147, Glu310 and Trp318, that seem to be important
for the activity improvement, in that they are present in
both compound 3 and compound 8, the two most active
cyclopeptides. The proposed binding site is situated not
far from the location previously identified by docking
studies as the binding site for JOM-6 [50,51]. The
importance of the key residues defining the binding
pocket, and determined by site-directed mutagenesis, is
confirmed also for this class of cyclopeptides. Despite
the absence of the charged nitrogen, all of the studied
CPPs show an interaction with Asp147. Furthermore, in
orientation 2, the role played by Glu229 in the proposed
EM-2 binding model [54] seems to be played by Glu310,
because both residues are located at the entrance of the
binding pocket, in a flexible loop structure, and there-
fore they are available for interaction with the ligands.
The two main orientations of the peptides were then
refined through hybrid QM ⁄MM geometry optimiza-
tion. This procedure highlighted a further, strategic
interaction between d-Trp3 and Trp293 of the CPPs in
orientation 2. Obviously, this interaction is absent in
the reversed orientation 1. The improved contact
between d-Trp3 and Trp293 is of particular interest.
Indeed, it has been suggested that after binding of the
Fig. 13. Superimposition of the conformations of compound 3 in
orientation 1 (green), and in orientation 2 (red), and JOM-6 (in blue),
docked into the binding site of MOR. The three important pharma-
cophoric centers are shown.
Fig. 14. Correlation between the experi-
mental (DGexp) and docking (DGdock) free
energies calculated in the ligand-binding
domain of the MOR model. Relevant statis-
tical parameters are also included.
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agonist JOM-6, Trp293 of TMH VI is forced to rotate
to form an efficient stacking interaction with Tyr1 of
the ligand [51]. The rearrangement of Trp293 would be
accompanied by a rigid 20 rotation of TMH VI, lead-
ing to the formation of a polar crevice delimited by
TMH III, TMH VI, and TMH VII. In particular, this
mechanism induces TMH VI to move towards
TMH V. The overall helix movement would be respon-
sible for the rearrangement of polar residues in the
cytoplasmatic region, so determining the activation of
the G protein. Accordingly, the strong stacking inter-
action of d-Trp3 with Trp293 might be implicated in
the modulation of helix motions needed for the activa-
tion of the receptor after binding of compound 3.
Finally, in order to assess the contribution of the
QM ⁄MM polarization to the ligand, the interaction
energy between compound 3 and the environment was
calculated. Despite the small movements of the binding
site residues, the QM ⁄MM methods confirm the
enhanced binding ability of orientation 2 with respect
to orientation 1, measurable by a difference in the
binding energy of  21 kcalÆmol)1 ()9180 and
)9201 kcalÆmol)1 for orientations 1 and 2, respec-
tively), a difference that is almost unpredictable con-
sidering only the differences in the binding site
composition or in the steric hindrance. When the
ligand reaches the binding site, it can be polarized by
the asymmetry in charge distribution of the residues
with permanent dipole moments (Ser, Thr, Asn, Tyr,
Trp, Cys and His) located on the surface of the bind-
ing site, and this polarization effect can be obtained by
using the QM description of the ligand. Looking at
the electronic structure of the ligands in their bounded
conformations, we can observe that both orientations
tend to support the superimposition of their dipole
moments with that of the binding site (Fig. 15).
This conformation is able to promote the binding
because the additional dipole moment induced in the
ligand results in a stronger Coulomb interaction
between compound 3 and the binding site, ensuring a
better dipole–dipole interaction with the MOR envi-
ronment. For both orientation 1 and orientation 2, if
the adopted conformations of the ligand are coherent
with this scheme, the additional dipole moment contri-
butions caused in the binding site environment give
rise to a larger overall dipole moment, with a net con-
tribution to the drug–receptor interaction energy that
can vary from )1 to )5 kcalÆmol)1. This effect is par-
ticularly important for orientation 2, where the better
dipole–dipole interaction with the MOR environment
results in an overall dipole moment of 133 Debye, as
compared to the value obtained for orientation 1
(70 Debye). Then, from the analysis of the results of
the QM ⁄MM optimization, it appears that principal
effect is again the electronic one. This effect, together
with the steric hindrance, can be used to direct the
binding to the receptor and to score the relative values
of the binding energy.
Conclusions
The recent discovery of the atypical CPP compound 3,
c[YpwFG], which activates MOR even when deprived
of a protonable amine, could be of interest for devel-
Fig. 15. Representation of the QM part of the MOR–compound 3 complex in orientation 1 (left) and orientation 2 (right). In both cases, the
ligand is represented as a ball and stick, and the amino acid portion is shown as a stick. The dipole moments for the binding site (red arrow)
and for the ligand (blue arrow) are shown in the bottom left.
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oping novel analgesics characterized by alternative
ligand–receptor interaction modes. In this work, we
have analyzed plausible 3D structures of compound 3
and its analogs compounds 4–8, accounting for the
diverse binding affinities towards MORs. The compari-
son of the structures of the CPPs and JOM-6 sug-
gested that the CPPs probably interact with the
receptor by adopting peculiar orientations.
On the basis of spectroscopic analysis, MD, and
molecular docking studies, we have restricted the
investigation to two orientations of the ligands within
the receptor pocket. We first explored the possible
binding positions and binding modes of the flexible
ligands within the rigid receptor environment, and the
solutions obtained from this docking were subse-
quently optimized by means of the combined
QM ⁄MM approach, using a flexible receptor environ-
ment that allows simulation of the receptor adaptation
upon ligand binding.
The first orientation recalls the traditional models of
ligand–receptor complexes reported in the literature
(see Discussion). On the other hand, molecular dock-
ing analysis furnished a second, plausible, reversed ori-
entation, characterized by a more favorable binding
energy after QM ⁄MM geometry optimization, showing
the indole NH of d-Trp3 hydrogen bonded to Asp147
of TMH III, plus other interactions with key receptor
residues. The absence of the ionic interaction can be
partially compendated for by the hydrogen bond of
d-Trp3 with Asp147. Also, a highly favorable dipole–
dipole interaction was calculated for compound 3 in
the orientation 2, indicating that ligand polarization
induced by the protein environment represents a note-
worthy contribution to the overall binding energy.
This second orientation represents an unusual mode
of receptor binding and activation. The good correla-
tion between the observed receptor affinities and the
calculated interaction energies for compounds 3–8 sub-
stantiates the reliability of the model.
In the proposed model, after the initial contact, the
reciprocal induced fit [55] of both ligand and receptor
would allow the transmission of a deformation from
the binding site to the transmembrane domain [51], in
particular for the strong interaction between the
d-Trp3 aromatic side-chain and Trp293 of TMH VI.
Experimental procedures
General methods
Unless stated otherwise, standard chemicals were obtained
from commercial sources (Sigma-Aldrich, St Louis, MO,
USA; or Invitrogen, Carlsbad, CA, USA) and used without
further purification. Flash chromatography was performed
on Merck silica gel 60 (230–400 mesh), and solvents were
simply distilled. ESI MS was performed with an
HP 1100MSD. Analytical RP-HPLC was performed on an
HP Series 1100, with an HP Hypersil ODS column (4.6 lm
particle size, 250 mm), diode-array detector 210 nm (eluant:
from 90 : 10 to 20 : 80 H2O ⁄CH3CN in 15 min, followed by
10 min of 20 : 80 H2O ⁄CH3CN). Semipreparative RP-
HPLC was performed on an HP Series 1100 using a Zorbax
Eclipse XDB C18 column, 7 lm particle size, 21.2 · 150
mm (eluant: 60 : 40 H2O ⁄CH3CN for 5 min, then from
60 : 40 H2O ⁄CH3CN to 100% CH3CN in 15 min).
Peptide synthesis [36]
Peptides were prepared by standard solid phase peptide
synthesis using Fmoc chemistry. Wang resin (0.5 g,
0.5 mmolÆg)1) suspended in 9 : 1 dichloromethane ⁄ dimeth-
ylformamide (5 mL) was treated with a solution of Fmoc-
Phe-OH (0.21 g, 0.5 mmol) and HOBt (0.07 g, 0.5 mmol)
in dimethylformamide (2 mL), followed by N,N¢-dic-
yclohexylcarbodiimide (0.11 g, 0.5 mmol) and catalytic dim-
ethylaminopyridine. The mixture was mechanically shaken
for 4 h, and then filtered, and the resin was washed with
dimethylformamide (5 mL), CH3OH (5 mL), and dichlo-
romethane (5 mL). To end-cap unreacted OH groups, the
resin was suspended in dichloromethane (5 mL), treated
with Ac2O (0.3 mL) and pyridine (0.3 mL), and mechani-
cally shaken. After 0.5 h, the mixture was filtered and the
resin was washed twice with dimethylformamide (5 mL),
CH3OH (5 mL), and dichloromethane (5 mL).
The Fmoc group was cleaved from the resin with 4 : 1
dimethylformamide ⁄ piperidine (4 mL) under mechanical
shaking. After 15 min, the mixture was filtered, and the
resin was washed with dichloromethane (5 mL) and treated
under mechanical shaking with a second portion of 4 : 1
dimethylformamide ⁄ piperidine. After 30 min, the mixture
was filtered, and the resin was washed twice with dimethyl-
formamide (5 mL), CH3OH (5 mL), and dichloromethane
(5 mL).
The following residues were introduced by means of the
same procedure described above, without catalytic dimeth-
ylaminopyridine, and with the exclusion of the end-capping
step. Coupling efficacy was determined by means of Kaiser
or chloranil tests.
Peptide cleavage
The N-deprotected resin was suspended in a mixture of tri-
fluoroacetic acid (4.7 mL), H2O (0.15 mL), and PhOH
(0.15 mL), and mechanically shaken at room temperature.
After 2 h, the mixture was filtered, the resin was washed
twice with 10% trifluoroacetic acid in Et2O (5 mL), and
twice with Et2O, and each filtrate was poured into 100 mL
of ice-cold Et2O. The resulting precipitate was filtered, and
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the crude solid peptide–trifluoroacetic acid salt was crystal-
lized from MeOH ⁄Et2O. Peptides were characterized by
analytical RP-HPLC and ESI MS (see General methods).
Peptide cyclization
The peptides (0.1 mmol) were dissolved in dry dimethylfor-
mamide (40 mL) and treated while being magnetically stir-
red with NaHCO3 (4.5 mmol) and DPPA (0.3 mmol) at
room temperature. After 2 days, the mixture was filtered,
the solvent was distilled at reduced pressure, and the resi-
due was transferred in a separating funnel. The residue was
diluted with water (5 mL), and the mixture was extracted
with EtOAc (4 · 20 mL). The collected organic layers were
dried over Na2SO4, and the solvent was evaporated at
reduced pressure. The oily residue was purified by flash
chromatography over silica gel (eluant: EtOAc ⁄MeOH
97 : 3), followed by semipreparative RP-HPLC (see General
methods), affording the cyclopeptides in 50–70% yield, 93–
97% pure by analytical RP-HPLC analysis (see General
methods). Peptides were characterized by analytical
ESI MS (see General methods).
Binding assays
Rat brain, without cerebellum, was weighed and homoge-
nized in 10 volumes of ice-cold 0.32 m sucrose ⁄ 10 mm
Tris ⁄HCl (pH 7.4 at 4 C). The homogenate was centri-
fuged at 850 g for 10 min at 4 C, and the surnatant was in
turn centrifuged at 75 000 g for 20 min at 4 C. The result-
ing pellet was suspended in 10 volumes of 50 mm
Tris ⁄HCl ⁄ 100 mm NaCl (pH 7.4 at 4 C), as incubation
buffer, and incubated for 1 h at 37 C. to remove any
endogenous opioid ligands. After a final centrifugation at
75 000 g for 20 min at 4 C, the pellet was stored at
)80 C for up to 2 weeks.
Protein concentration was determined according to
Lowry et al. [56]. [3H]DAMGO was used as a l-selective
radioligand (1 nm); specific activity was 64 CiÆmmol)1,
Kd = 4.85 nm, and Bmax = 48 fmolÆmg
)1 protein; n = 3.
Nonspecific binding was determined in the presence of
100 lm DAMGO. The incubation buffer consisted of
50 mm Tris ⁄HCl, 0.1% BSA (pH 7.4 at 4 C), and 2 mm
EDTA. To prevent any peptidase degradation, the follow-
ing protease inhibitors were added to the binding buffer:
captopril 25 lgÆmL)1, bacitracin 0.2 mgÆmL)1, leupeptin
10 lgÆmL)1, phenylmethylsulfonyl floride 0.19 mgÆmL)1,
and aprotinin 5 KIUÆmL)1. DORs and KORs were blocked
with 0.01 m H-Tyr-d-Ala-Gly-Phe-d-Leu-OH and 0.01 m
U50 488, respectively.
The mixture (1 mL) was incubated for 1 h at room tem-
perature, and then filtered under vacuum through glass
fibers [GFB, Whatman, soaked for 1 h in 0.1% poly(ethyl-
eneimine)] and washed with ice-cold washing buffer (50 mm
Tris ⁄HCl, pH 7.4 at 4 C). The ligand–receptor complex
radioactivity retained in the filter was measured by liquid
scintillation spectrometry using a scintillator after 12 h of
incubation in scintillation cocktail. All assays were per-
formed in triplicate, and repeated at least three times. Stock
solutions (10)2 m) were in dimethylsulfoxide or
MeOH ⁄ 0.1 m HCl (1 : 1 v ⁄ v).
NMR experiments
NMR spectra were recorded using 5 mm tubes, using
0.01 m peptide in dimethylsulfoxide-d6, at 400 MHz and
room temperature. Chemical shifts are reported as d values
relative to the solvent peak. VT-1H-NMR experiments were
performed over the range 298–348 K. 2D spectra were
acquired in the phase-sensitive mode and processed using a
90 shifted, squared sine-bell apodization. The unambigu-
ous assignment of the resonances was performed by
Gradient COSY and heteronuclear multiple bond correla-
tion (HBMC) analysis. GradientCOSY experiments were
recorded with a proton spectral width of 9595.8 Hz.
Gradient HMBC experiments were recorded with a proton
spectral width of 9595.8 Hz and a carbon spectral width of
36 199.1 Hz, selecting a spin coupling constant of 8 Hz.
ROESY experiments were recorded with a 300 ms mixing
time with a proton spectral width of 3087.8 Hz.
Conformational analysis in solution
The data derived from 2D-ROESY in dimethylsulfoxide-d6
were analyzed by restrained MD, using nongeminal inter-
proton distances as constraints. When possible, an analysis
of 3JNH–Ha and
3JHa–Hb coupling constants was used to
estimate the torsion angles [57]. The eventual presence of
Hai–Hai + 1 cross-peaks was used to infer the presence of
cis peptide bonds. Also, the difference between the
13C-NMR chemical shifts (data not shown) of Pro-Cb and
Pro-Cc (e.g. at 26.7 and 24.3, respectively, for d-Pro2 in
compound 3) confirmed the configuration of the preceding
peptide bond (a Dd Cb–Cc of 4–6 p.p.m. indicates a trans
peptide bond, whereas a Dd Cb–Cc of 8–10 p.p.m. is
expected for a cis one) [58]. The gas-phase MD simulations
were conducted at 298 K by using an AMBER [39] force
field with a distance dependent e = 4.0 r. In the restrained
MD, a 50 ps simulation at 1200 K was used for generating
100 random structures that were subsequently subjected to
a 20 ps restrained MD simulation with a 50% scaled force
field at the same temperature, followed by 20 ps at 1200 K
with full restraints, after which the system was cooled in
10 ps to 50 K. The distance force constant was 7 kcalÆmo-
l)1ÆÅ)2; x-bonds were set at 180, using a force constant of
16 kcalÆmol)1ÆÅ)2. Only ROESY-derived constraints were
included in the restrained MD. ROESY intensities were
classified according to a calibration against the intensity of
geminal protons. Very strong, strong, medium and weak
signals were associated with distances of < 2.3, < 2.8,
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< 3.5 and < 4.8 Å, respectively. Geminal couplings ad
other obvious correlations were discarded.
The resulting structures were minimized with 3000 cycles
of steepest descent and 3000 cycles of conjugated gradient;
convergence was at 0.01 kcalÆÅ)1Æmol)1. The structures that
showed the lowest internal energy and the least number of
violations of the experimental data were selected and ana-
lyzed.
Simulations in explicit water were performed at 298 K,
again using the AMBER force field in a 30 · 30 · 30 box
of standard TIP3P models of equilibrated water [59,60],
with a minimum solvent–solute distance of 2.3 Å, at con-
stant temperature and pressure (Berendsen scheme [61],
bath relaxation constant 0.2).
Computational procedures
Molecular modeling and graphics manipulations were per-
formed using optimized Mac OSX versions of namd [62],
autodock [30], autodock tools [63] and ucsf chimera
software packages [64] on an Apple MacPro quad-Xeon
workstation running Mac OSX Tiger (version 10.4.9).
Model building and geometry optimizations of the studied
compounds were accomplished with the gaussian 03 (6-
31G* base set) [43] quantum mechanical calculations pack-
age. The outputs from autodock and all modeling studies
as well as images were built with pymol [42] and accel-
rys dsvisualizer (http://www.accelrys.com) and rendered
with povray [65]. ucsf chimera was used to calculate the
hydrogen bond distances measured between the hydrogen
and its assumed binding partner. The MOR–substrate com-
plex was constructed by docking the ligand into the equili-
brated MOR structure using autodock. Then, the system
was equilibrated with a series of minimizations interspersed
by short MD simulations; the resulting structures were used
as the starting model for the gaussian 03 QM ⁄MM study,
as well as for a 1.2 ns MD simulation, and the structure
resulting from MD simulation was then optimized by
means of an AMBER force field.
Preparation of the MOR–substrate systems
As the experimentally determined 3D structure of a MOR
is not yet available, a MOR 3D model was generated
using modeller according to the protocol of comparative
modeling [66]. The sequence of the MOR polypeptide
chain was retrieved from the Swiss-Prot database and
aligned using the PAM250 matrix, using ‘gap-open’ and
‘gap-elongation’ penalties of 10 and 0.05, respectively. The
alignment was then manually refined to ensure a perfect
alignment of the highly conserved residues. The homology
model of the MOR receptor was built by introducing into
the modeller program [66] the X-ray rhodopsin crystal
structure (Protein Data Bank code: 1f88), selected as the
template structure from the Protein Data Bank using a
gapped blast of protein similarity search module.
The MOR model was then checked through auto-
dock tools and ucsf chimera to guarantee system con-
formity with the molecular modeling programs (in
particular, the names of the side chains that must be con-
gruent with the AMBER force field used). The amino acid
chain of the MOR model was terminated with )COO)
and )NH3
+ groups in their zwitterionic forms, and the
polar hydrogen atoms were added in their calculated posi-
tions. The protonation state was set to the normal ioniza-
tion state at pH 7.0 for all the ionizable residues (in
particular, Asp147, Asp216, Glu229 and Glu310) and His
residues (His223, His297 and His319 set to Nd1), and
both the topology and connectivity of the molecule had
been created. Model building was followed by energy
minimization up to an energy gradient lower than 10)4
kcalÆmol)1ÆÅ)1, choosing AMBER as a force field as
implemented in the namd package. Thus, the model was
compared with the agonist peptide-incorporated structural
model of MOR constructed by Mosberg et al. [50] (model
title: OPRM_RAT_AD_JOM-6, available from the
Mosberg Lab studies on peptide synthesis and molecular
recognition at the University of Michigan in Ann Arbor
[67]), and no inconsistencies were observed (rmsd value of
0.20 Å).
The experimental conformations preferentially adopted in
dimethylsulfoxide solution were used as starting structures,
whereas that of JOM-6 was obtained from the original
Mosberg MOR model. The ligands were then optimized
using gaussian 03 at the B3LYP ⁄ 6-31G* level [43,68], and
atomic charges were assigned using the Gasteiger–Marsili
formation, which uses the type of atomic charges used
in calibrating the autodock empirical free energy func-
tion [69].
Molecular docking
To test the ability of the molecular docking program to
reveal the ligand binding to our MOR, the JOM-6 mole-
cule was initially docked, and the orientation of the result-
ing lowest-energy structure was compared with that
present in the original Mosberg model [50,51]. A perfect
superposition (rmsd 0.33 Å) was obtained, a result that
demonstrates the ability of autodock to locate the
JOM-6 binding mode. The docking into the MOR model
was performed with autodock (version 4) [30,64]. The
autodock suite uses an automated docking approach that
allows ligand flexibility, and it is able to locate docking
poses in a consistent way with respect to the X-ray crystal
structures [32,70]. Default parameters (including a dis-
tance-dependent dielectric ‘constant’) were used as
described in the autodock manual, and both the protein
crystal structure and the ligands were prepared for dock-
ing by following the default protocols (except for those
changes mentioned below). autodock uses an empirical
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scoring function that is able to approximate the binding
free energies, because it includes a solvation free energy
term. Because of the absence of information on the bind-
ing region for compounds 3, 7, and 8, the docking process
was performed in two steps. In the first, the docking pro-
cedure was applied to the whole protein target, without
imposing any binding site, using the so-called ‘blind dock-
ing’ approach [31,71]. A box of 40 · 40 · 40 Å, centered
at the middle of the MOR model, was used with a grid
resolution of 0.5 Å. The resulting docked conformations
were clustered into families of similar binding modes, with
an rmsd clustering tolerance of 2 Å. In almost all cases,
the lowest docking energy conformations were included in
the largest cluster found (which usually contains 80–100%
of total conformations). Otherwise, the lowest docking
energy conformations were considered to be the most sta-
ble orientations. In the second step, we docked the ligands
in the binding site found in the first step (‘refined dock-
ing’). This time, a box of 20 · 20 · 20 Å, centered on the
best scored conformation obtained in the first step (corre-
sponding to x-, y- and z-values of )13.71, 9.56 and
0.47 Å, respectively), was considered, with a grid resolu-
tion of 0.300 Å. Movement of the ligands was limited to
inside this search space during docking. Atomic solvation
parameters were assigned to the protein, and the default
parameters for the Lamarckian genetic algorithm were
used as the search protocol, except for the maximum
number of energy evaluations, which was changed to
10 million (the population size was raised to 500). For the
GA algorithm, the default parameters were kept for muta-
tion, crossover, and elitism. The docked energy also
includes the ligand internal energy or the intramolecular
interaction energy of the ligand. autodock also reports a
binding free energy that excludes the ligand internal
energy but includes a torsional free energy term for the
ligand based on the number of rotatable bonds. The
resulting orientations were again clustered into families,
considering a rmsd clustering tolerance of 2.0 Å, and the
lowest docking energy conformations were equilibrated for
1.2 ns by unrestrained MD, choosing AMBER as a force
field as implemented in the namd package. The simula-
tions were performed at constant temperature and pressure
(NPT ensemble) in a periodic cubic box of TIP3P water
molecules. The bond distances and bond angles of water
were constrained using the settle algorithm [72], and the
bond lengths within the protein were constrained with the
lincs algorithm [73]. The coupling time was set to 1.0 ps,
and the isothermal compressibility was set to
4.6 · 10)5Æbar)1. The protein, ligand and solvent were
independently coupled to a temperature of 298 K with a
coupling time of 0.1 ps, and the pressure was held at
1 bar, with a coupling time of 0.2 ps, using a Berendsen
thermostat to maintain the constant temperature and pres-
sure. The time step used was 1.0 fs. Snapshots of the
MOR–substrate systems were saved every 0.2 ps, and 6000
snapshots were saved. Hydrogen bonds and contacts were
automatically identified using the ‘contact’ module of
CCP4 [74] and ucsf chimera, and the other interactions
were identified visually.
Hybrid QM ⁄ MM calculations
In the current study, we used the pseudo-bond ab initio
QM ⁄MM approach as implemented in gaussian 03 [43,68].
This methodology circumvents the major deficiency of the
conventional link-atom QM ⁄MM approach by providing a
consistent and well-defined ab initio QM ⁄MM potential-
energy surface. For the QM ⁄MM calculations, the MOR–
ligand system resulting from the docking study was first
partitioned into a QM subsystem and an MM subsystem.
The reaction system used a smaller QM subsystem consist-
ing of the cyclopeptide and side chains of the amino acids
within 3.5 Å from orientations 1 and 2, whereas the rest of
the protein (the MM subsystem) was treated using the
AMBER force field, together with a low memory conver-
gence algorithm. The boundary problem between the QM
and MM subsystems was treated using the pseudo-bond
approach. With this MOR–substrate QM ⁄MM system, an
iterative optimization procedure was applied to the
QM ⁄MM system, using B3LYP ⁄ 3-21G* QM ⁄MM calcula-
tions, leading to an optimized structure for the reactants.
The convergence criterion used was set to obtain an energy
gradient of < 10)4, using the twin-range cutoff method for
nonbonded interactions, with a long-range cutoff of 14 Å
and a short-range cutoff of 8 Å.
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